Literature DB >> 7834371

Expression of CDK5 (PSSALRE kinase), a neural cdc2-related protein kinase, in the mature and developing mouse central and peripheral nervous systems.

H Ino1, T Ishizuka, T Chiba, M Tatibana.   

Abstract

CDK5 is a cdc2-related protein kinase that is known to be highly expressed in mature brain. In this study, we obtained a mouse CDK5 cDNA by screening an adult mouse cDNA library. Northern blot analysis demonstrated that the mouse CDK5 mRNA was expressed especially highly in brain, and moderately in kidney, testis and ovary. In brain the expression of CDK5 is already seen at embryonal 12.5 days (E12.5), and it gradually increases through the embryonal stage. After birth, the expression is maintained at a high level to adulthood. In situ hybridization demonstrated that the expression of CDK5 mRNA was distributed in neurons throughout the brain, spinal cord and peripheral ganglia, especially in the hippocampal pyramidal cells, cerebellar Purkinje cells, cortical neurons, olfactory mitral cells, mesencephalic and motor trigeminal nuclei and trigeminal ganglion. In any portion, no apparent expression was observed in glia. During development, the expression of CDK5 was already seen at E12.5 intensely in trigeminal and dorsal root ganglia, and moderately and diffusely in the central nervous system. The expression pattern of CDK5 is quite in contrast with that of CDC2. The fact that CDK5 is expressed in terminally differentiated non-dividing neurons predicts an alternative function(s) in addition to controlling the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834371     DOI: 10.1016/0006-8993(94)91197-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4.

Authors:  Luis M Schang; Andrew Bantly; Priscilla A Schaffer
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 2.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

3.  Gene expression of matrix metalloproteinase-1 (interstitial collagenase) and matrix metalloproteinase-3 (stromelysin-1) in basal cell carcinoma by in situ hybridization using chondroitin ABC lyase.

Authors:  R Tsukifuji; Y Sakai; A Hatamochi; H Shinkai
Journal:  Histochem J       Date:  1997-05

Review 4.  Neuronal migration and the role of reelin during early development of the cerebral cortex.

Authors:  Yves Jossin
Journal:  Mol Neurobiol       Date:  2004-12       Impact factor: 5.590

5.  Nucleocytoplasmic transfer of cyclin dependent kinase 5 and its binding to puromycin-sensitive aminopeptidase in Dictyostelium discoideum.

Authors:  Robert J Huber; Danton H O'Day
Journal:  Histochem Cell Biol       Date:  2011-07-16       Impact factor: 4.304

6.  Cyclin-dependent kinase 4 and cyclin D1 are required for excitotoxin-induced neuronal cell death in vivo.

Authors:  H Ino; T Chiba
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

7.  Molecular Roles of Cdk5 in Pain Signaling.

Authors:  Elias Utreras; Akira Futatsugi; Tej Kumar Pareek; Ashok B Kulkarni
Journal:  Drug Discov Today Ther Strateg       Date:  2009-09

8.  Amino acid sequence conservation of the algesic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain.

Authors:  Andrei V Chernov; Albert G Remacle; Swathi K Hullugundi; Piotr Cieplak; Mila Angert; Jennifer Dolkas; Veronica I Shubayev; Alex Y Strongin
Journal:  FEBS J       Date:  2018-08-27       Impact factor: 5.542

9.  PKCdelta regulates cortical radial migration by stabilizing the Cdk5 activator p35.

Authors:  Chun-tao Zhao; Kun Li; Jun-tao Li; Wang Zheng; Xu-jun Liang; An-qi Geng; Ning Li; Xiao-bing Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-24       Impact factor: 11.205

Review 10.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.